Striaterminalis, I must admit that seeing them raise the dose to 2100 mg (30% over the MTD) did not enhance my confidence very much. Having Dr. Stoll announce that he's stepping down, 6 weeks before D-Day, doesn't have me jumping for joy either. I knew that day would eventually come, but I definitely didn't appreciate the timing of the announcement.
Concerning the trials, while Cortex may not have any 'official' info about the RD trial results so far, I think the German researchers do, for a simple reason -- the RD-2 trial is designed with a 3rd cohort, the dose of which is flexible - 'higher or lower as needed'. This trial design indicates that they expect the German researchers to be able to gauge efficacy in the 900 mg and 1500 mg cohorts in spite of the trial being blinded. The fact that they've decided to jump way above MTD suggests that the efficacy at the lower doses may not be overly robust. If activity at 1500 mg had been clearly strong, they might have still decided to go to 2100 mg anyway, just to see what happens, but in that case (strong results at 1500 mg) the SHM should have been more ebullient, especially since apparently Tran had recently been to the German site, so he likely knows the score.
Well, I guess we'll just have to wait and see. One positive is that, as Neuro said, the RD trial doesn't necessarily have to show statistical significance - a reasonably strong trend should be enough for a pharma deal.
Market Data 
Markets 
AI
